Chiusura precedente | 1,6000 |
Aperto | 1,6500 |
Denaro | 1,5800 x 300 |
Lettera | 1,6100 x 400 |
Min-Max giorno | 1,5450 - 1,6200 |
Intervallo di 52 settimane | 1,0800 - 2,7000 |
Volume | |
Media Volume | 556.808 |
Capitalizzazione | 108,366M |
Beta (5 anni mensile) | 1,23 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,9400 |
Prossima data utili | 07 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 22,60 |
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY. Details of the presentation appear below: C
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and investments. SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-
Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in the third quarter of 2023SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of